All IPAC members participating in the meeting updated their declaration of interest ahead of the meeting. Other meeting participants, including observers, do not take part in the decision-making and are thus not required to complete a declaration of interest.

Eight members reported relevant interests, all of which were assessed not to constitute a conflict of interest and these individuals will take part in full in all discussions. All the reported relevant interests are summarized below:

**Robin Biellik**
- Received consultancy fees from WHO/EURO to develop strategic plans and verification guidelines for measles elimination. The work was concluded in 2011. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from WHO/EMRO to develop verification guidelines for measles elimination. This work was concluded in 2012. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from WHO/HQ to support measles elimination activities. The work was concluded in 2013. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from ECDC to prepare report on pertussis. The work was concluded in 2013. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from UNICEF/Ethiopia to support measles elimination activities. The work was concluded in March 2014. This interest was assessed as personal, non-specific and financially significant. *

**Xavier Bosch-Capblanch**
- His institution received consultancy fees in 2009 and 2010 from WHO/HQ to conduct a study on unvaccinated children as well as an analysis on the relationship between the unvaccinated and gender. This interest was assessed as non-personal, non-specific and financially significant. *
- His institution received consultancy fees in 2010 from GAVI to conduct a baseline study on the advanced market commitment for pneumococcal vaccine and to develop the health systems strengthening knowledge bank. This interest was assessed as non-personal, non-specific and financially significant. *
- His institution received consultancy fees from WHO in 2011 and 2012 to present evidence on rotavirus vaccine and to analyse coverage data generated from Demographic and Health Surveys and Multiple Indicator Cluster surveys, and present the evidence on rotavirus and pneumococcal to SAGE. This interest was assessed as non-personal, non-specific and financially significant. *

**Francois Gasse**
- Received consultancy fees from WHO to develop guidelines to sustain maternal and neonatal tetanus elimination. This work is on-going. This interest was assessed as personal, non-specific and financially significant. *
- Received consultancy fees from UNICEF for three consultations in Madagascar on immunization equity. This work is on-going. This interest was assessed as personal, non-specific and financially significant. *
- Receives consultancy fees from Becton Dickinson to provide technical advice on innovative technology concept for vaccine carriers and vaccine vials, to help review design/method for a field survey to test user acceptance and decision-maker acceptance, including the review of the survey results. This work was completed in 2013. This interest was assessed as personal, non-specific and financially significant. *

Christopher Morgan
- Received consultancy fees from WHO/HQ over the period 2008-2011 to support work on hepatitis B birth dose. This included conducting a field trial in Papua New Guinea, writing a systematic literature review and organising a technical consultation. The work was concluded in 2011. This interest was assessed as non-personal, non-specific and financially significant. *
- Sits on the External Technical Advisory Board (ETAB) organized by Agence de Médicine Préventive to provide advice on the methodology, implementation and data analysis on optimal approaches of using Uniject to deliver DTP-HepB-Hib in Senegal and Vietnam. This study is funded by Crucell. This interest was assessed as non-personal, non-specific and financially insignificant.

Folake Kio-Olayinka
- Was employed by Immunization Basics/JSI as Deputy Country Representative of Nigeria, which ceased in 2009. This interest was assessed as personal, non-specific and financially significant. *

Jean-Marc Olivé
- Receives consultancy fees from McKing, an institution financed by the Bill & Melinda Gates Foundation, to support polio eradication activities in priority African countries. The work is on-going and is primarily focused in Chad. This interest was assessed as personal, non-specific and financially significant. *

Robert Steinglass
- Sits on WHO’s Vaccine Product and Packaging Advisory Group (VPPAG). This interest was assessed as personal, non-specific and financially insignificant.
- Sits on the External Technical Advisory Board (ETAB) organized by Agence de Médicine Préventive to provide advice on the methodology, implementation and data analysis on optimal approaches of using Uniject to deliver DTP-HepB-Hib in Senegal and Vietnam. This study is funded by Crucell. This interest was assessed as non-personal, non-specific and financially insignificant.
- Unrelated to agenda of this IPAC meeting, his institution is involved in many aspects of immunization with grants and contracts from BMGF, GAVI, UNICEF, USAID, and WHO.
- For cited activities, Mr Steinglass has never received lecture fees, honoraria nor research grants from industry.

Carla Vizzotti
- Received support from Novartis and Pfizer to attend the following meetings as a participant:
  - 2009 Infectious Diseases Society America (IDSA) Philadelphia
  - 2010 International Symposium on Pneumococci & Pneumococcal Diseases (ISPPD) Tel Aviv, Israel
  - 2009 XIII Congreso de la Sociedad Latinoamericana de Infectologia Pediatrica (SLIPE) Guayaquil, Ecuador
This interest was assessed as non-personal, non-specific and financially insignificant.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 10,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a "significant shareholding".